Objectives-To investigate the efficacy of transdermal glyceryl trinitrate given continuously and with a nocturnal nitrate free period.
Abstract
Objectives-To investigate the efficacy of transdermal glyceryl trinitrate given continuously and with a nocturnal nitrate free period.
Design-Double blind placebo controlled study with two parallel limbs.
Setting-Multicentre trial.
Patients-52 patients randomised to receive either continuous treatment (23 patients) or intermittent treatment with an individually titrated dose (29 patients) for 14 days: both treatments were compared with placebo in a crossover fashion.
Intervention-Continuous treatment with 10 mg per 24 hours of transdermal glyceryl trinitrate or intermittent transdermal glyceryl trinitrate titrated to give an arbitrary 10 mm Hg drop in systolic blood pressure (mean dose 18-2 mg) given over approximately 16 hours.
Main outcome measure-Treadmill exercise stress testing and ambulatory monitoring of the ST segment after 14 days' treatment.
Results-After 14 days' intermittent treatment resting supine and standing systolic blood pressure fell by 7 5 mm Hg (95% confidence interval 2-7 to 12-2) and 9 0 mm Hg (95% CI 3-4 to 14-5) respectively (p < 0-01); resting heart rate was unchanged. Mean heart rate at 1 mm ST segment depression rose by 11 9 beats/ min (CI 1-1 to 23-7) (p < 0-05), mean time to onset of angina increased by 59 seconds (CI Patients were specifically excluded from study if they had had a documented myocardial infarction in the preceding three months; electrocardiographic abnormalities that might have interfered with the interpretation of the ST segment; a diastolic blood pressure > 100 mm Hg; or significant renal, hepatic, haematological, or other clinically relevant concurrent conditions.
All eligible patients entered a one week, open run-in period and were maintained on sublingual glyceryl trinitrate alone. They performed a symptom limited treadmill exercise stress test according to a modified Bruce protocol. To be included in the treatment phases of the study patients had to show a positive response to sublingual glyceryl trinitrate during a second exercise stress test performed at least one hour and up to three hours later, 10 minutes after the patient had taken one (500 rg) sublingual tablet of glyceryl trinitrate. The response was defined as positive if the exercise time needed to cause 1 mm ST segment depression was >2 minutes longer than during the first exercise test. During the second test, the workload was not increased beyond that required to produce 1 mm of ST segment depression in the first test; this avoided the false negative results caused by a higher workload.
The 85 patients who responded to sublingual glyceryl trinitrate were randomised to receive either a placebo controlled continuous or a placebo controlled intermittent treatment regimen lasting one month. After randomisation to the treatment regimens patients were re-randomised to active treatment followed by placebo treatment or vice versa in a balanced crossover design (2 x 2 weeks). During continuous treatment patients were treated with transdermal patches delivering 10 NS, not statistically significant at p < 0 05 level.
ANGINA ATTACK RATES
The incidence of angina during treatment with placebo was low (6-6 attacks/week). Neither active treatment significantly changed this rate. The consumption of glyceryl trinitrate tablets was similarly unaltered. The incidence of nocturnal episodes was similar in all active and placebo treatment phases.
WITHDRAWALS FROM TREATMENT
Of the 85 patients who were randomised to treatment, 25 patients were withdrawn from the study, 11 receiving continuous treatment and 14 receiving intermittent treatment. A total of 17 (20%) patients were withdrawn because of headache (14 active, three placebo), and four patients (4 7%) withdrew because of local rashes (three active, one placebo). In two patients angina became worse on active intermittent treatment. One patient collapsed suddenly and died during the day while receiving active intermittent treatment. In addition, one patient on continuous treatment had so much difficulty with shift work patterns that he withdrew from the study.
Discussion
The results of this study support the conclusion that transdermal glyceryl trinitrate significantly increases the total duration of treadmill exercise, the time to onset of angina, and the heart rate at 1 mm ST segment depression when these variables were measured 3-5 hours after dosing and after two weeks' treatment when individually titrated doses were used intermittently. A significantly lower systolic blood pressure beneficially affected the ratepressure product. In contrast, the continuous period of 12 hours seemed to prevent the development of tolerance, and prolongation of exercise duration was seen during the daytime. 24 In this study, however, there were nine patients who fulfilled the defined criteria for a significant increase in rest angina during the nitrate-free periods during active intermittent treatment; in addition, the results for exercise testing before the reapplication of the patch the following morning were less good than with placebo. This has raised the question that "rebound" may be a real if rare phenomenon in patients treated with transdermal glyceryl trinitrate as monotherapy. 
